XERS

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Wall Street analysts forecast XERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XERS is 12.33 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Xeris Biopharma Holdings Inc revenue for the last quarter amounts to 74.38M USD, increased 37.06 % YoY.

Xeris Biopharma Holdings Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Xeris Biopharma Holdings Inc (XERS) has 394 emplpoyees as of December 15 2025.

Today XERS has the market capitalization of 1.19B USD.